Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

NCT01627132 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shimousa Hematology Study Group

Collaborators